Gaudium IVF Reports Strong FY26 Growth; IPO Funds Largely Unused

Consolidated Revenue: ₹104.36 crore
Profit for the year (Consolidated): ₹24.49 crore

Reader Takeaway: Strong revenue and profit growth alongside significant unutilized IPO funds.

What just happened

Gaudium IVF and Women Health Ltd announced its financial results for the quarter and year ended March 31, 2026. The company reported a consolidated revenue of ₹104.36 crore and a consolidated profit of ₹24.49 crore for FY26.

Standalone performance also showed growth, with revenue at ₹71.58 crore and profit at ₹22.29 crore for the same period. The auditor's opinion was unmodified.

Why this matters

The results indicate robust business expansion. Consolidated revenue saw a significant jump of 47.57% compared to FY25, while consolidated profit grew by 27.69%. Standalone revenue and profit also showed healthy increases of 21.32% and 19.64%, respectively. This suggests strong operational performance and market demand for the company's services.

The backstory

Gaudium IVF completed its Initial Public Offering (IPO) in February 2026, raising ₹90.00 crore through a fresh issue. The funds were intended for specific purposes, including the establishment of new IVF centers, loan repayment, and general corporate purposes.

What changes now

While the financial performance is positive, a key point for investors is the utilization of IPO proceeds. As of March 31, 2026, ₹50 crore earmarked for new IVF centers and ₹20 crore for loan repayment remain unutilized. Only ₹0.97 crore out of ₹12.28 crore for general corporate purposes has been used.

The management has also commented on potential impacts from new Labour Codes, stating they do not expect a material financial impact on obligations like gratuity and compensated absences.

Risks to watch

Investors will closely monitor the deployment of the substantial unutilized IPO funds towards expansion plans and debt reduction. Delays or inefficiencies in fund utilization could impact future growth prospects.

Peer comparison

No direct peer comparison was provided in the filing.

Context metrics (time-bound)

• Consolidated Revenue FY26: ₹104.36 crore (up 47.57% from ₹70.72 crore in FY25).
• Consolidated Profit FY26: ₹24.49 crore (up 27.69% from ₹19.18 crore in FY25).
• Standalone Revenue FY26: ₹71.58 crore (up 21.32% from ₹59.00 crore in FY25).
• Standalone Profit FY26: ₹22.29 crore (up 19.64% from ₹18.63 crore in FY25).
• IPO Funds Unutilized (as of Mar 31, 2026): ₹70.00 crore (₹50 crore for new centers + ₹20 crore for loan repayment).

What to track next

Investors should look for clear timelines and execution updates on the utilization of IPO funds for setting up new IVF centers and repaying loans. Continued strong revenue and profit growth will also be critical.